Ep 87: INTerpath-001 Press Release - August 2026

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualized neoantigen therapy plus pembrolizumab for resected stage IIB to IV melanoma. No data were shared, only descriptive findings of "statistically signficant" and "clinically meaningful" results. As James puts it, one of these is binary, the other is subjective.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(95)

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
psykodrama
hvordan-har-du-det-mann
leger-om-livet
fryktlos
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-skravla-gar
rss-ekteskapet
foreldreradet
morten-ramm-lar-kakla-ga-til-du-sovner
rss-garne-damer
hjernesterk
rss-kunsten-a-leve
treningsprat
klimaks
rss-lopedrommen
rss-loping-for-nybegynnere
rss-kull